NCT04111107: Precision Medicine for Patients With Identified Actionable Mutations

NCT04111107
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy, Immunotherapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Other, Therapeutic Antibody, Endocrine (Hormone) Therapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Must be a patient at Wake Forest Baptist Comprehensive Cancer Center or one of its satellites; Patients must have progressed through at least two lines of treatment
Exclusions: 
https://ClinicalTrials.gov/show/NCT04111107

Comments are closed.

Up ↑